PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

Blood

Volumn 122, Issue 6, 2013, Pages 969-980

  Tung, Stephanie ^a,b   Shi, Yonghong ^a   Wong, Karry ^b,c   Zhu, Fang ^b,c   Gorczynski, Reg ^b,c   Laister, Robert C ^d   Minden, Mark ^b,d   Blechert, Anne Kareen ^e   Genzel, Yvonne ^e   Reichl, Udo ^e   Spaner, David E ^a,b,f  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ALANINE; ALEMTUZUMAB; DEXAMETHASONE; GLUTAMIC ACID; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; LACTIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MIFEPRISTONE; OFATUMUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROPIONIC ACID; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVATE KINASE; PYRUVATE KINASE M2; PYRUVIC ACID; RITUXIMAB; SUCCINIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CARRIER PROTEIN; FATTY ACID; GLUCOCORTICOID; MEMBRANE PROTEIN; OXYGEN; PROPIONIC ACID DERIVATIVE; THYROID HORMONE; THYROID HORMONE BINDING PROTEINS; THYROID HORMONE-BINDING PROTEINS;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SIZE; CHRONIC LYMPHATIC LEUKEMIA; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVITY; FATTY ACID OXIDATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR VOLUME; UPREGULATION; ANIMAL; CELL MEMBRANE; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LIPID METABOLISM; METABOLISM; NONOBESE DIABETIC MOUSE; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

ADIPOCYTES; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MEMBRANE; CULTURE MEDIA, CONDITIONED; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS; GENE EXPRESSION REGULATION, LEUKEMIC; GLUCOCORTICOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPID METABOLISM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; OXYGEN; PHOSPHORYLATION; PPAR ALPHA; PROPIONATES; THYROID HORMONES;

EID: 84886880074     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-489468     Document Type: Article

References (40)

1. Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119(18):4101-4107.
2. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1): 128-130.
3. Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia. 2012;26(5): 1144-1145.
4. Hench PS, Kendall EC, Slocumb CH, Polley HF. Adrenocortical Hormone in Arthritis: Preliminary Report. Ann Rheum Dis. 1949;8(2):97-104.
5. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1): 55-89.
6. Flammer JR, Rogatsky I. Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol. 2011; 25(7):1075-1086.
7. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 2010;10(5):365-376.
8. Kfir-Erenfeld S, Sionov RV, Spokoini R, Cohen O, Yefenof E. Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations. Leuk Lymphoma. 2010;51(11): 1968-2005.
9. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 2011;117(9): 2668-2680.
10. Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Park C, Choi K, Bickel PE. OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J Lipid Res. 2006;47(2):450-460.
11. Garcia-Gonzalo FR, Izpisúa Belmonte JC. Albumin-associated lipids regulate human embryonic stem cell self-renewal. PLoS ONE. 2008;3(1):e1384.
12. Janke R, Genzel Y, Wahl A, Reichl U. Measurement of key metabolic enzyme activities in mammalian cells using rapid and sensitive microplate-based assays. Biotechnol Bioeng. 2010;107(3):566-581.
13. Gibon Y, Blaesing OE, Hannemann J, et al. A Robot-based platform to measure multiple enzyme activities in Arabidopsis using a set of cycling assays: comparison of changes of enzyme activities and transcript levels during diurnal cycles and in prolonged darkness. Plant Cell. 2004;16(12):3304-3325.
14. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
15. Spaner DE, Lee E, Shi Y, et al. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 2013;27(5):1090-1099.
16. Wong KK, Brenneman F, Chesney A, et al. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res. 2012;72(19):4931-4943.
17. Agarwai MK. The antiglucocorticoid action of mifepristone. Pharmacol Ther. 1996;70(3): 183-213.
18. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
19. Lin X, Adams SH, Odle J. Acetate represents a major product of heptanoate and octanoate beta-oxidation in hepatocytes isolated from neonatal piglets. Biochem J. 1996;318(Pt 1):235-240.
20. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res. 2012;18(20):5554-5561.
21. Baig NA, Taylor RP, Lindorfer MA, et al. Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma. 2012;53(11): 2218-2227.
22. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100(5):1765-1773.
23. Krauss S, Brand MD, Buttgereit F. Signaling takes a breath—new quantitative perspectives on bioenergetics and signal transduction. Immunity. 2001;15(4):497-502.
24. Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010;90(1):367-417.
25. Holzer RG, Park EJ, Li N, et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell. 2011;147(1):173-184.
26. Harmon GS, Lam MT, Glass CK. PPARs and lipid ligands in inflammation and metabolism. Chem Rev. 2011;111(10):6321-6340.
27. Schulze A, Downward J. Flicking the Warburg switch-tyrosine phosphorylation of pyruvate dehydrogenase kinase regulates mitochondrial activity in cancer cells. Mol Cell. 2011;44(6): 846-848.
28. Pond CM. Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids. 2005;73(1):17-30.
29. Brunengraber H, Roe CR. Anaplerotic molecules: current and future. J Inherit Metab Dis. 2006; 29(2-3):327-331.
30. Elzein E, Ibrahim P, Koltun DO, et al. CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability. Bioorg Med Chem Lett. 2004;14(24):6017-6021.
31. Xu HE, Stanley TB, Montana VG, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002;415(6873):813-817.
32. Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta. 2007;1771(8):1082-1093.
33. Grandér D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy. 2009; 5(8):1198-1200.
34. Buentke E, Nordström A, Lin H, et al. Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. Blood Cancer J. 2011;1(7):e31.
35. Hulleman E, Broekhuis MJ, Pieters R, Den Boer ML. Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia. Haematologica. 2009;94(9):1322-1324.
36. Harada M, Pokrovskaja-Tamm K, Söderhäll S, Heyman M, Grander D, Corcoran M. Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(10): 2041-2050.
37. Samudio I, Harmancey R, Fiegl M, et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010;120(1):142-156.
38. Schafer ZT, Grassian AR, Song L, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 2009;461(7260):109-113.
39. Zaugg K, Yao Y, Reilly PT, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011;25(10): 1041-1051.
40. Carracedo A, Weiss D, Leliaert AK, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest. 2012;122(9):3088-3100.